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Background: The neuronal ceroid lipofuscinoses (NCLs, or Batten disease) comprise the most common Mendelian
form of childhood-onset neurodegeneration, but the functions of the known underlying gene products remain
poorly understood. The clinical heterogeneity of these disorders may shed light on genetic interactors that modify
disease onset and progression.
Case presentation: We describe a proband with congenital hypotonia and an atypical form of infantile-onset,
biopsy-proven NCL. Pathologic and molecular work-up of this patient identified CLN5 mutations as well as a
mutation-previously described as incompletely penetrant or a variant of unknown significance-in POLG1, a nuclear
gene essential for maintenance of mitochondrial DNA (mtDNA) copy number. The congenital presentation of this
patient is far earlier than that described for either CLN5 patients or affected carriers of the POLG1 variant
(c.1550 G> T, p.Gly517Val). Assessment of relative mtDNA copy number and mitochondrial membrane potential in
the proband and control subjects suggested a pathogenic effect of the POLG1 change as well as a possible
functional interaction with CLN5 mutations.
Conclusions: These findings suggest that an incompletely penetrant variant in POLG1 may modify the clinical
phenotype in a case of CLN5 and are consistent with emerging evidence of interactions between NCL-related
genes and mitochondrial physiology.
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The neuronal ceroid lipofuscinoses (NCLs, also known
as Batten disease) comprise a group of at least 10 dis-
tinct lysosomal storage diseases with overlapping clinical
features including pigmentary retinal degeneration and
visual failure in most cases, progressive motor and cog-
nitive decline, epilepsy, movement disorder, and eventual
premature death [1]. Eight genes are linked to
childhood-onset NCL, but many late-onset clinical forms
as well as some pediatric forms remain without identi-
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reproduction in any medium, provided the orother eukaryotic disease models suggest that lipid and
protein trafficking defects in the endocytic and lyso-
somal systems underlie NCL disease biology (reviewed
in [2-4]).
The pathologic hallmark of most forms of NCL is the
lysosomal accumulation of subunit c of the mitochon-
drial ATP synthase complex [5]. Our previous studies in
a genetically accurate model of juvenile NCL (CLN3)
demonstrated that this accumulation is preceded by
endosomal-lysosomal trafficking defects leading to
impaired autophagy as well as by altered mitochondrial
morphology, decreased basal ATP levels, and increased
sensitivity to oxidative stress [6]. Indeed altered tran-
scriptional regulation of mitochondrial oxidative phos-
phorylation is an early molecular event in genetically
accurate murine cell culture models and may therefore
contribute to disease onset or progression [7]. Similar
transcriptional alterations have been described inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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form of NCL caused by mutations in DNAJC5, which
encodes the synaptic protein cysteine-string protein
alpha (CSPα) [8].
Here we describe a patient with an atypical and excep-
tionally early-onset form of CLN5-associated NCL who
also carries a variably penetrant dominant mutation (p.
Gly517Val) in POLG1, a nuclear gene encoding the cata-
lytic subunit of mitochondrial DNA polymerase, which
is critical for maintenance of mtDNA copy number and
mitochondrial physiology. We present clinical and func-
tional evidence for a possible interaction between an
NCL-related gene and a gene involved in mitochondrial
homeostasis.Case presentation
The proband is the only child of healthy, non-
consanguineous parents of northern European descent
and was delivered by an uncomplicated Caesarean section
for breech presentation at 37 weeks' gestation with a birth
weight of 5 lbs, 6 oz. The Apgar score at one and five min-
utes was 8. The mother had no prior pregnancies. Shortly
after birth, the child was noted to have diffuse hypotonia,
hypoactive reflexes, and roving eye movements. Height
and weight has remained steady at about the 25th percent-
ile, and head circumference continues to be normal. Diffi-
culty tracking visual stimuli was noted at about 4 weeks,
and ophthalmologic evaluation has revealed decreased vis-
ual acuity, mild bilateral macular pigmentary changes, nor-
mal refractive indices, bilateral ptosis, and disconjugate,
nystagmoid eye movements. Frequent interruptible staring
spells and episodes of lip-smacking and hand-wringing
were noted soon after birth. No clear EEG correlate was
observed at 5 or 20 months, and no overt myoclonic or
generalized tonic-clonic seizures were observed. Evaluation
at 4 months of age put her global development at the level
of a newborn. MRI imaging at 4 and 21 months showed
mild diffuse cerebral atrophy and bilateral posterior peri-
ventricular white-matter changes on T2 FLAIR sequences
(Figure 1a) without evidence of restricted diffusion by
diffusion-weighted imaging. At the time of her most recent
examination at 25 months, the patient continued to show
the foregoing features and, in addition, failed to initiate
motor movements, showed impaired upgaze, and had
increased lower extremity tone when placed in upright
position but without long-tract signs such as hyperreflexia.
There is no family history of visual failure or seizures,
but the proband’s mother does have a distant family his-
tory of cognitive delay without clear etiology. Interest-
ingly, the mother herself carries a diagnosis of
vitelliform macular dystrophy, a condition associated
with lipofuscin accumulation in the retinal pigment epi-
thelium [9]. At the time of the mother’s evaluation, itwas unclear whether this retinal process might represent
a forme fruste of NCL.
Methods
Sequencing and multiplex ligation-dependent probe
amplification
Total genomic DNA was extracted from peripheral
blood specimens using standard manual methods (Qia-
gen, Valencia, CA). Sanger sequencing of the coding
regions and exon-intron boundaries of CLN3, CLN5,
CLN6, MFSD8, CLN8, and CTSD was performed on a
3130xl Genetic Analyzer (Applied Biosystems, Foster
City, CA). Primer sequences are available on request.
Multiplex ligation-dependent probe amplification
(MLPA) of the four exons of CLN5 was performed as
described [10].
Comparative genomic hybridization
Comparative genomic hybridization (CGH) was per-
formed in the Cytogenetics Core of the Dana Farber-
Harvard Cancer Center using an oligo-based 60K cus-
tom array platform (Agilent Technologies, Palo Alto,
California, USA) containing 52,275 probes across the
genomic backbone and 553 probes tiling the CLN5
locus at chr13:77550160–77580653, giving ~50-bp reso-
lution for this region. Probes with unique genomic map-
pings were used, where possible, and were filtered by
predicted melting temperature, unique genomic map-
pings, repeat content, and for the presence of known
SNPs. The DNA was fragmented, labeled, and hybri-
dized according to standard Agilent protocols. The array
was scanned on an Agilent Scanner with 2-micron reso-
lution. Intensity values were obtained using Agilent's
Feature Extraction software and were subsequently ana-
lyzed using Agilent's Genomic Workbench software to
identify aberrant regions. Coordinates reflect human
genome build 19 [11].
Quantitative PCR
Relative mtDNA copy numbers from total DNA
extracted as above were measured by real-time PCR as
described [12] with modifications noted here. DNA was
also extracted from fibroblast cultures (described below)
grown in 25 mM glucose or 25 mM galactose. Forward
and reverse primer sequences for the mtDNA gene target
ND2 were 5'-TGTTGGTTATACCCTTCCCGTACTA-3'
and 5'-CCTGCAAAGATGGTAGAGTAGATGA-3'. For-
ward and reverse primer sequences for the nuclear gene
target GAPDH were 5'-CATCATCCCTGCCTCTACTG-
3' and 5'-TTGGCAGGTTTTTCTAGACG-3'. Real-time
PCR was performed using SYBR Green (Roche) accord-
ing to the manufacturer's instructions and analyzed on a
LightCycler 480 instrument (Roche) using the following









Figure 1 (A) Cranial FLAIR MRI of the proband at 21 months of age showing mild diffuse cerebral atrophy, particularly in the frontal
lobes, and bilateral posterior periventricular white matter changes. (B) Transmission electron micrographs of a representative lymphocyte
from the proband showing GROD-like material (arrows) and curvilinear inclusion bodies (inset) characteristic of late-infantile NCL and variant
forms. Magnification 26,000X; inset: 105,000X. Scale bar, 1 μm. (C) Upper panel: Electropherogram from Sanger sequencing of the proband
showing the heterozygous c.61 C> T change in exon 1 of CLN5, which predicts a p.Pro21Ser missense change. Lower panel: A portion of the
tiling microarray spanning the CLN5 locus showing a ~2.8 kb one-copy loss (chr13:77569502–77572394) present in the proband but not in either
parent. Coordinates reflect human genome build 19.
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10 seconds, 56°C for 10 seconds, and 72°C for 10 sec-
onds. Threshold cycle (Ct) values of each target were
determined for each individual in triplicate in the same
qPCR run. Relative mtDNA copy number was calcu-
lated as 2 x (2ΔCt), where ΔCt is CtGAPDH – CtND2. An
unpaired, two-tailed t test was used to assess the statis-
tical significance.
Assay of mitochondrial membrane potential and ETC
activity
Fibroblast cultures were derived from skin biopsies
obtained under an IRB-approved protocol in accordancewith the Helsinki Principles. Subjects used in this study
included the proband and an unrelated patient with
compound heterozygous CLN5 mutations (exon 3
c.671 G>A, p.Trp224X and exon 4 c.1103_1106del, p.
Lys368SerfsX15), no known mutations in genes related
to mitochondrial function, and a typical clinical course,
including onset of seizures at age 7. A normal control
fibroblast line (GM8330) was obtained from the Coriell
Cell Repository (Camden, NJ). Fibroblasts of compar-
able passage number (4 to 6) were grown under stand-
ard conditions in DMEM supplemented with 10% FBS.
Relative mitochondrial membrane potential in these
cell lines were measured in triplicate (5x103 cells/well
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dye JC1 (Cell Technology, Inc., Mountain View, CA)
using a fluorescence plate reader (SpectraMax M2,
Molecular Devices, Inc., Sunnyvale, CA) as per the
manufacturer’s instructions.
Activity of electron transport chain complexes II-IV
was measured by established spectrophotometric meth-
ods (Center for Inherited Disorders of Energy Metabol-
ism, Case Western Reserve U., Cleveland, OH) in cells
grown to confluence under the above conditions.
Results
Several clinical features in the proband, including pos-
sible seizure activity, profound global developmental
delay, cortical atrophy, and apparent pigmentary retin-
opathy prompted an initial diagnostic workup directed
towards a form of neuronal ceroid lipofuscinosis. Ultra-
structural examination of a buffy coat preparation
obtained at 4 months of age showed frequent
membrane-bound curvilinear inclusions, material resem-
bling GRODs (granular osmiophilic deposits), and occa-
sional fingerprint-like profiles (Figure 1b and data not
shown). Similar findings were present in a concurrent
skin biopsy (not shown). GRODs and curvilinear profiles
are characteristic of the classic infantile (CLN1) and
classic late-infantile (CLN2) forms of NCL, respectively,
but may be seen in other forms of NCL [1]. Fingerprint
profiles are characteristic of juvenile NCL (CLN3) but
may be seen in NCL subtypes, often in combination with
other ultrastructural forms. Peripheral blood screening
for the enzymes PPT1 and TPP1, deficiencies of which
produce CLN1 and CLN2, respectively, was within nor-
mal limits (63 pmol/hr [range 21–123] and 51 pmol/hr
[range 40–279], respectively; testing performed at the
Biochemical Genetics Laboratory of Seattle Children’s
Hospital). Sequencing of CTSD, which encodes the lyso-
somal aspartyl protease cathepsin D and underlies a rare
congenital form of NCL (CLN10) [13], showed 3 known
single nucleotide polymorphisms (SNPs).
Having ruled out the typical earliest forms of NCL,
we proceeded to test for variant late-infantile forms of
NCL. Molecular analysis of CLN5 revealed a maternally
inherited heterozygous point mutation of a conserved
residue in exon 1, c.61 C>T/p.Pro21Ser, and an appar-
ently de novo one-copy deletion spanning exon 3 of
CLN5 detected by MLPA and predicted to produce a
frameshift and truncated product of 174 amino acids
(p.Lys163GlufsX11). The deletion was confirmed by til-
ing microarray of the CLN5 locus (Figure 1c). A de
novo mutation in an NCL-related gene has not been
reported to our knowledge. To address the possibility
of non-paternity, we completely sequenced the intronic
and exonic regions of the CLN5 gene in the proband
and parents and found a SNP pattern compatible withinheritance of the maternal and paternal haplotypes at
this locus (data not shown). The c.61 C>T change
was absent in over 200 control chromosomes of pre-
dominantly European ancestry but was found as an iso-
lated change in a teenage boy with progressive
neurologic decline but no further clinical details. The
c.61 C>T variant has a carrier frequency of ~0.2%
(22/9554 chromosomes) among controls in the Exome
Variant Server [14]. This is comparable to the carrier
frequency of the more common known pathogenic
NCL alleles in the European population. Testing for
other NCL-related genes, including CLN3, CLN6,
MFSD8, and CLN8, showed no pathogenic changes.
A concurrent work-up for the proband’s congenital
hypotonia, a feature not typically associated with NCL,
included normal testing for Prader-Willi syndrome,
spinal muscular atrophy, and an extensive panel of lyso-
somal storage diseases other than the NCLs. Screens for
disorders of amino acid and fatty acid metabolism were
also within normal limits. Of note, serum lactate levels
were elevated on 2 separate occasions at 2.7 mEq/L and
3.3 mEq/L (range 0.7-1.8 mEq/L), with normal corre-
sponding pyruvate levels. The patient had a normal
karyotype, and a targeted 105K microarray (Signature
Genomics) showed no pathogenic copy number changes.
An extensive screen of mtDNA point mutations was
negative, as was a screen for mitochondrial genomic
deletions and rearrangements by Southern blotting (test-
ing performed at the Molecular Diagnostics Laboratory
of the University of Pittsburgh Medical Center). How-
ever, testing of mutations associated with whole mito-
chondrial genome depletion revealed a heterozygous,
maternally inherited change, c.1550 G>T, p.Gly517Val,
in POLG1, a nuclear gene encoding the catalytic subunit
of the polymerase for mtDNA (Figure 2a).
In the absence of a muscle or liver biopsy, we sought
to probe the possible functional effect of the POLG1
mutation by measuring relative mtDNA copy number in
peripheral blood and fibroblasts as described previously
[12]. Quantitative PCR of a mtDNA gene target (ND2)
normalized to a nuclear gene target (GAPDH) showed
an ~45% reduction in the proband in relative mtDNA
copy number compared to age-matched controls and an
~30% reduction compared to an unrelated CLN5 pa-
tient, described in the methods, with a more typical clin-
ical course (Figure 2b). Furthermore, the carrier mother
showed a relative mtDNA copy number lower than that
of the father as well as older controls. We also assayed
relative mtDNA copy number in subconfluent cultures
of fibroblasts from the proband, the unrelated CLN5 pa-
tient, and a normal control, GM8330. The proband cell
line showed a 30-35% relative reduction in mtDNA both
under standard growth conditions (+glucose) and when
stressed with a condition that deprives cells of glycolytic
BD
C
carrier of POLG1 c.1550G>T, p.Gly517Val
affected compound heterozygote of CLN5 c.61C>T,
p.Pro21Ser and de novo exon 3 deletion
asymptomatic carrier of CLN5 c.61C>T, p.Pro21Ser 
congenital hypotonia 


























































































































































Figure 2 (A) Pedigree summarizing molecular analysis of CLN5 and POLG1 in proband and her parents. (B) Results of real-time PCR
analysis of relative mtDNA copy number in peripheral blood from the proband, her parents, an unrelated CLN5 patient with a typical clinical
course, and normal controls. Ages are noted in parentheses. Data are shown as the mean± SEM of triplicate measurements; *, P< 0.01,
**, P< 0.05, two-tailed t test. (C) Relative mtDNA copy number in cultured skin fibroblasts from the proband, unrelated CLN5 patient, and normal
control (GM8330). Fibroblasts were grown under standard conditions (25 mM glucose) or under conditions of metabolic stress (25 mM galactose).
Data are shown as the mean± SEM of triplicate measurements; *, P< 0.05, two-tailed t test. (D) Measurement of relative mitochondrial membrane
potential using the ratiometric dye JC-1 in fibroblast lines from the proband, an unrelated CLN5 patient with a typical clinical course, and a
normal control subject (GM8330). E600 is the emission peak corresponding to normal mitochondrial polarization; E535 is the emission peak
corresponding to depolarization. Data are shown as the mean± SEM of triplicate measurements; *, P< 0.01, two-tailed t test.
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ation as an energy source (+galactose) (Figure 2c). To-
gether these results suggest a possible interaction
between CLN5 and POLG1 with respect to their effect
on mtDNA copy number.
To determine whether these changes in mtDNA copy
number might be associated with changes in overall
mitochondrial physiology, we assayed mitochondrialmembrane potential in the fibroblast lines used above.
Basal mitochondrial potential in the proband, as mea-
sured by the ratiometric dye JC-1, was reproducibly
about half that of the other two cell lines (Figure 2d),
consistent with the relative effects on mtDNA copy
number seen in Figure 2c. To determine whether this al-
teration of membrane potential may reflect altered elec-
tron transport chain activity, the activities of complexes
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Although these activities were within normal limits for
all 3 lines (data not shown), we cannot exclude the pos-
sible contributions of altered complex I activity,
decreased ATP production, and reactive oxygen species
production to the lower mitochondrial membrane po-
tential in fibroblasts from the proband.
Discussion
Each molecular subtype of NCL shows remarkable
phenotypic heterogeneity with respect to age of onset,
severity of clinical features, and their order of presenta-
tion, raising the possibility of genetic modifiers that
converge on NCL-associated pathways. Extreme devia-
tions from the usual clinical course may be particularly
informative. The case we present here, with onset of
symptoms shortly after birth, represents an atypical and
unusually early-onset form of CLN5-associated NCL,
reported cases of which range in age of onset from 4
to 23 [10]. The presence of additional atypical features
in this case, such as congenital hypotonia and nystag-
moid eye movements, suggested co-inheritance of
modifying factors.
Molecular work-up for these latter features revealed a
variably penetrant mutation (c.1550 G>T, p.Gly517Val)
in the linker region between the exonuclease and poly-
merase domains of POLG1, a nuclear gene encoding the
catalytic subunit of the only known human polymerase
that replicates and repairs mtDNA [15]. Most character-
ized mutations of POLG1 cause a depletion of total
mtDNA and a secondary reduction of the electron trans-
port components necessary for oxidative phosphoryl-
ation. Depending on their location in the POLG1
protein, other mutations may additionally cause dele-
tions within the mitochondrial genome or increase the
rate of nucleotide misincorporation [16,17]. POLG1-
related disorders include a spectrum of overlapping and
heterogeneous clinical phenotypes including Alpers syn-
drome (progressive hepatocerebral degeneration, leading
to developmental regression, intractable epilepsy, hepatic
failure, and death), the ataxia-neuropathy spectrum, spi-
nocerebellar ataxia with epilepsy, mitochondrial neuro-
gastrointestinal encephalopathy, parkinsonism, and
progressive external ophthalmoplegia (PEO) [18]. Most
of these disorders are inherited in an autosomal reces-
sive manner with the major exception being autosomal
dominant forms of PEO.
The p.Gly517Val mutation found in the family
described here has been previously reported to manifest
as an incompletely penetrant dominant mutation with
variable clinical features that include seizures and myop-
athy ranging in age of onset from one to sixteen years
[19]. In one 3-generation family with this mutation, the
phenotype was most severe in a subject that also carried,in trans, a second variably penetrant substitution, p.
Glu1143Gly, in the polymerase domain of POLG1 [20].
Two half siblings heterozygous for p.Gly517Val showed
early-onset seizures (one at 13 months of age and the
other at 7 years of age), myoclonus, hypotonia, and
developmental delay, but their carrier mother was un-
affected [21], much as was the case in our family. To-
gether, these findings suggest that other genetic factors
elicit or modify the pathogenic effect of the p.Gly517-
Val substitution and possibly other changes in POLG1.
While we acknowledge that the co-inheritance of the
CLN5 mutations and POLG1 change in the proband
may simply represent an unusual coincidence, the clin-
ical and functional data presented here suggest a genetic
interaction between them. Specifically, an incompletely
penetrant POLG1 change (p.Gly517Val) in combination
with CLN5 mutations produced a clinical phenotype in
the proband far earlier than that reported for either gen-
etic disorder alone. Furthermore, relative mtDNA copy
number in the proband was significantly reduced com-
pared to age-matched controls and an unrelated CLN5
patient with a typical clinical course.
Together, these observations are consistent with accu-
mulating evidence of mitochondrial pathology in the
NCLs. Fibroblasts from patients and animal models
with certain subtypes of NCL show alterations in mito-
chondrial morphology, respiratory chain complex activ-
ity, and basal ATP synthesis (reviewed in [22]). Gene
pathway analysis of altered transcripts in genetically ac-
curate murine cell culture models of CLN3 and CLN6
suggest that dysregulation of oxidative phosphorylation
may be a proximal player in these forms of the disease
[7]. In addition, human cell lines from CLN5/CLN9
patients show altered transcriptional regulation of mul-
tiple subunits of cytochrome c oxidase (respiratory
complex IV) [23,24]. Finally, fibroblasts from both
CLN1 and CLN6 patients show altered mitochondrial
distribution, density, and membrane potential, although
CLN1 fibroblasts showed only a mild decrease in com-
plex II-III activity and CLN6 fibroblasts showed normal
complex I-IV activity [25]. Fibroblasts from the proband
described here also showed altered membrane potential
without apparent effects on complex activity (specific-
ally complexes II-IV), possibly reflecting compensatory
changes of respiratory activity in cultured cells or other
contributors to altered membrane potential such as
reduced ATP production or dysregulated reactive oxy-
gen species production.
Interestingly, genetic defects in lysosomal storage,
such as variants of glucocerebrosidase associated with
Gaucher disease [26], and defects in mitochondrial
DNA synthesis, including mutations in POLG1 [27,28],
independently contribute to forms of parkinsonism,
suggesting that impairments in lysosomal and
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pathways of neurodegeneration. It will be of interest to
probe potential genetic interactions between these
pathways in established animal models of NCL [1] and
aberrant mtDNA synthesis [29,30].Conclusions
We present an atypical and exceptionally early-onset
case of CLN5 whose clinical and molecular phenotype
may be modified by a variably penetrant mutation, p.
Gly517Val, in the linker region of the mtDNA polymer-
ase POLG1. Functional in vitro analysis of relative
mtDNA copy number and mitochondrial membrane po-
tential supports the pathogenicity of the POLG1 change
and suggest a possible genetic interaction between an
NCL-related gene and another involved in mitochondrial
homeostasis. Polymorphisms or mutations in genes
related to mitochondrial function may represent a novel
group of modifiers relevant to the highly heterogeneous
NCL disorders.Consent
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